Adaptive laboratory evolution in *S. cerevisiae* highlights role of transcription factors in fungal xenobiotic resistance

Sabine Ottilie¹,¹², Madeline R. Luth¹,¹², Erich Hellemann²,¹³, Gregory M. Goldgof¹,¹³, Eddy Vigil¹, Prianka Kumar¹, Andrea L. Cheung¹, Miranda Song¹, Karla P. Godinez-Macias¹, Krypton Carolino¹, Jennifer Yang¹, Gisel Lopez¹, Matthew Abraham¹, Maureen Tarsio³, Emmanuelle LeBlanc⁴, Luke Whitesell⁴, Jake Schenken¹, Felicia Gunawan¹, Reysa Patel¹, Joshua Smith¹, Melissa S. Love⁵, Roy M. Williams¹,¹¹, Case W. McNamara⁵, William H. Gerwick⁶, Trey Ideker⁷, Yo Suzuki⁸, Dyann F. Wirth⁹,¹⁰, Amanda K. Lukens¹⁰, Patricia M. Kane³, Leah E. Cowen⁴, Jacob D. Durrant² & Elizabeth A. Winzeler¹

In vitro evolution and whole genome analysis were used to comprehensively identify the genetic determinants of chemical resistance in *Saccharomyces cerevisiae*. Sequence analysis identified many genes contributing to the resistance phenotype as well as numerous amino acids in potential targets that may play a role in compound binding. Our work shows that compound-target pairs can be conserved across multiple species. The set of 25 most frequently mutated genes was enriched for transcription factors, and for almost 25 percent of the compounds, resistance was mediated by one of 100 independently derived, gain-of-function SNVs found in a 170 amino acid domain in the two Zn₂C₆ transcription factors *YRR1* and *YRM1* ($p < 1 \times 10^{-100}$). This remarkable enrichment for transcription factors as drug resistance genes highlights their important role in the evolution of antifungal xenobiotic resistance and underscores the challenge to develop antifungal treatments that maintain potency.
Experimental evolution is an important method for studying evolutionary processes and is especially amenable to microorganisms given their short generation times, large population sizes, and ability to cryopreserve at distinct timepoints. The longest-running and largest-scale laboratory evolution experiment to date utilize *E. coli*—although the approach has been used successfully in additional microbes, including the eukaryote *S. cerevisiae*. While many laboratory evolution experiments focus on changing nutrient availability or culturing conditions, another application of in vitro evolution involves studying an organism’s evolutionary response to drug pressure. For example, many antibiotic resistance mechanisms have been identified and characterized through this method. A key challenge lies in identifying functional variants that contribute to the evolved phenotypes given the sheer number of mutation events; a recent sequencing study of 1011 yeast isolates have been identified and characterized through this method. A key challenge lies in identifying functional variants that contribute to the evolved phenotypes given the sheer number of mutation events; a recent sequencing study of 1011 yeast isolates identified 1,625,809 SNVs.

Systematic functional genomic studies are also used to understand drug-target interactions, but most rely on strain libraries in which the entire coding region is modified. For example, a set of homozygous and heterozygous knockout yeast strains was constructed which bear deletions in all genes in the genome. This set has been used to repeatedly and systematically identify knockout/knockdown lines that show sensitivity or resistance to a wide variety of different compounds and remains important. CRISPR-based, genome-wide knockout and knockdown studies and novel genome editing systems like base editors are also used in many organisms to identify drug targets or study processes such as the emergence of cancer drug resistance. A key limitation of such studies is that they will miss gain-of-function SNVs, which often drive natural adaptive evolution. Some examples of gain-of-function antibiotic resistance mechanisms include mutations that activate global transcription factors and mutations within the promoter region of resistance genes that result in their hyperproduction.

Here, we perform in vitro evolution and whole-genome analysis (IVIEWGA) in *S. cerevisiae* to delineate drug-target interactions with a large set of compounds and in the process, extensively characterize key features of the yeast resistome. Whole-genome sequencing of 355 evolved, compound-resistant clones showed only a few new coding variants per clone and that statistical approaches can be used to readily identify variants that modify phenotypes. As a proof-of-concept, we confirmed targets that were previously reported and identified additional resistance-conferring mutations for molecules with unknown mechanisms of action (MOA). We also observed enrichment for gain-of-function variants that affect transcription and confer resistance to multiple compounds.

### Results

#### Building a library of compounds that are active against a drug-sensitive yeast.

To understand how yeast evolves to evade the action of small molecules, identify genes contributing to resistance to uncharacterized small molecules, and hone in on domains that might contribute to compound-target interaction, we tested a collection of molecules for activity against *S. cerevisiae*. Since wild-type *S. cerevisiae* (strain S288C) requires higher compound concentrations to inhibit growth due to an abundance of drug export pumps (ABC transporters), in vitro selection would be impossible for many compounds. Therefore, to find compounds with activity against yeast at physiologically relevant concentrations, we used a modified *S. cerevisiae* strain, termed the “ABC16-Green Monster” (GM), in which 16 ABC transporters have been replaced with a green fluorescent protein (GFP). This has proven an excellent platform for in vitro drug selection and target identification experiments because of lower compound requirements.

Specifically, we evaluated compound libraries comprised of (1) drugs approved for human use with characterized MOAs, (2) well-known tool compounds, and (3) compounds from open-source libraries with demonstrated activity against eukaryotic pathogens, viruses, or tuberculosis (Supplementary Data 1). Commerically available compounds were tested in dose-response, while other libraries were initially tested at a single point concentration in biological duplicates of up to 150 µM, the maximum concentration possible to avoid in-assay DMSO toxicity. Compounds that showed at least 70% growth inhibition were subsequently tested in dose-response. Overall, the compounds of the assembled collection had drug-like physiochemical properties in terms of molecular weight and the number of hydrogen bond donors and acceptors.

In vitro resistance evolution and whole-genome analysis link compound structures to phenotype. Based on potency and compound availability, we selected 100 active compounds for follow-up in vitro evolution experiments to verify known MOAs, validate the use of this modified yeast strain in target deconvolution studies, and characterize crucial amino acids that disrupt compound binding when mutated. For each independent selection, ~500,000 cells derived from an ABC16-Green Monster single colony were grown to saturation (OD_{600} = 1.0–1.5) in 20 mL YPD media in the presence of sublethal compound concentration (in biological duplicates). After any independent selections reached saturation (OD_{600} = 1.0–1.5), ~500,000 cells were transferred to a new 20 mL culture containing increasing concentration of the compound until resistance was observed as measured by an increase in IC_{50} compared to the parental strain. Although growth rates of individual clones in culture could be variable, each dilution series (1 × 10^{9} cells) was nevertheless grown to saturation (on average ~14 generations amounting to a selection time of 5–20 days before plating on solid media). Cultures were considered resistant if they (1) continued to grow at compound concentrations 2–3-fold above the IC_{50} value of the untreated culture, and (2) had at least a 1.5-fold shift in IC_{50} value compared to the drug-naïve parental line (Supplementary Data 2). After a variable number of resistance cycles (R average = 2.93, range = 1–9), these resistant cultures were plated on drug-containing plates with the compound concentration of at least 2-fold IC_{50} to isolate single clones. We picked two independent colonies from the drug-containing plates to verify the resistance phenotype before submitting DNA for whole-genome sequencing. We attempted up to 12 independent selections per compound and obtained 1–12 resistant clones. Using this strategy, we isolated 355 clones selected against 80 compounds. The IC_{50} values of the resistant clones increased 1.5–5-fold for 121 clones, 5–10-fold for 101 clones, and >10-fold for 98 resistant clones (Supplementary Data 2, Supplementary Fig. 1). Some selections were performed in a modified ABC16-Green Monster clone with YRR1 deleted (see below). Culture contamination or poor compound availability accounted for most failed selections (20 compounds).

Next, resistant clones were sequenced to 55-fold average coverage (Supplementary Data 3) using a short-read methodology.
To detect mutations that arose during compound selection, we designed a custom whole-genome analysis pipeline and filtering method (see Methods). In total, we discovered 1405 mutations (1286 SNVs and 119 INDELS) that met the filtering criteria, with an average of 3.96 mutations per clone (Supplementary Data 4). 1117 mutations occurred in coding regions while 288 mutations were intergenic, intronic, or splice region variants. 781 unique genes were mutated across the dataset. We typically observed between 1 and 8 coding mutations per evolved clone per compound (Fig. 1c) with some variation. For 53 of the 80 compounds, we observed statistically significant ($p < 0.05$) reproducibility with respect to genes that were mutated, with enrichment considerably over that expected by chance (Fig. 1d).

For example, we obtained 13 independent TCMDC-124263-resistant clones with 52 mutations (38 coding), of which 10 were in a single gene, YRM1. Given that yeast has roughly 6000 genes, the Bonferroni-corrected probability of this enrichment by chance is $1.53 \times 10^{-25}$. For this example, 9 of the 10 nucleotide changes in YRM1 were clearly independent (Supplementary Data 4).

To further assess how our evolved mutations were driving the observed resistance phenotypes, we considered the types of mutations that arose during selection and compared them to a published set of 3137 mutations in yeast strains grown long-term in the absence of compound selection. We observed significantly different distributions in our compound-selected set than in the non-compound-selected set ($\chi^2, p < 0.0001$). For example, 39% of the nucleotide base transitions for 1286 SNVs in our compound-selected dataset were C to A or G to T, while for the 3137 transitions in the non-selected set, 40% were for A to G or T to C (Fig. 3a). Likewise, we observed a noteworthy difference in the coding changes. Among exonic selected mutations, 941 were nonsynonymous and 127 were synonymous. The estimated ratio of divergence at nonsynonymous and synonymous sites (dN/dS) was 2.62 across the dataset, indicating that drug treatment applied positive selection. In contrast, the neutral SNVs had a strong bias toward synonymous mutations (Fig. 3b). These data suggest that the observed mutations in our dataset are likely functional and could provide a selective advantage to the evolved clones.

We also assessed our large mutational dataset to identify broad insights into the functional impacts of different variant types. Synonymous and missense variants emerged in essential genes in ~20% of cases. This finding agrees with the literature, which suggests that only 20% of the yeast genome encodes essential genes. By this same metric, mutation types with more disruptive impacts, such as premature stop codons and frameshift variants, deviate strikingly from the expected genome-wide value of 20%. These mutations occur in essential genes only 4.9% and 7.0% of the time, respectively (Fig. 3c).

Copy number variants (CNVs) were detected through a coverage-based algorithm using the output from GATK DiagnoseTargets to identify contiguous genomic regions with increased read coverage relative to the parent. We observed 24 CNVs including...
apparent aneuploidy (11 times, occurring in 10 clones) and small, intrachromosomal amplification (13 times, occurring in 13 clones) (Supplementary Data 5). Altogether, we observed aneuploidy with 8 compounds, including BMS-983970, doxorubicin, etoposide, GNF-Pf-3582, GNF-Pf-4739, hygromycin B, CBR110, and wortmannin (Fig. 3d). This is perhaps not surprising given that aneuploidies arise in *S. cerevisiae* as a short-term stress response35.

We observed an amplification on chromosome XVI that involved the bZIP transcription factor, *ARR1*, for clones resistant to GNF-Pf-1618 and GNF-Pf-2740, as well as with four strains resistant to MMV665794. The strains Wortmannin-13R3a and CBR113-7R4a, both had chromosome XV CNVs that involved the transcription factors *YRR1* and *YRM1* (discussed below).

**Resistance-conferring intergenic mutations are rare.** Although intergenic mutations are frequently found in cells not subject to selection, mutations in promoters or 3' UTRs could confer resistance by increasing or decreasing transcript levels. To assess examples where this might be the case, we mapped the 271 intergenic mutations identified across the sequencing dataset to their nearest-neighbor coding genes and other genomic features (Supplementary Data 6). This analysis showed little enrichment, although we did observe several repeated mutations located in the intergenic promoter regions of a few genes that showed significance in our enrichment analysis. For example, we discovered three mutations upstream of the ergosterol biosynthesis and azole resistance gene *ERG9*36,37 in addition to seven *ERG9* coding region mutations. One of the *ERG9* intergenic mutations falls in its putative promoter region and was also observed in selections with compound AN7973 (Fig. 3e). Four coding and one noncoding mutation upstream of the start codon in the endoplasmic reticulum membrane protein and caspofungin resistance protein38, *CSG2*, were also observed. All five mutations are associated with selections to compound GNF-Pf-1618 and its close analog, KAAA725 (Fig. 3f). We also identified five mutations in the coding region of *PDR3*39, a zinc finger transcriptional regulator of the multidrug efflux, and an additional mutation was found downstream of the open reading frame (Fig. 3g). These examples demonstrate that intergenic mutations should not be entirely dismissed when considering the effects of variant types on observed phenotypes.

**CRISPR/Cas9 validation shows that most genes identified more than once confer resistance, but singleton mutations may not.** Because many mutations can co-occur and be non-

---

**Fig. 2** Generation of resistant yeast strains using a stepwise method of compound exposure. **a** To determine the degree of growth inhibition of small molecules, cultures derived from single colonies of the ABC16-Green Monster strain (GM) were exposed to various drugs and the IC50 determined. **b** For in vitro selections single colonies of GM were picked and grown to saturation in YPD media. 50 µl cells of a saturated culture (OD600 = 1) were inoculated into 50 mL tubes containing 20 mL of YPD media with a small-molecule inhibitor and grown until saturation. The starting drug concentration was the pre-determined IC50. **c** Upon reaching saturation cultures were diluted (1:400) into fresh media with increasing drug concentrations. **d** Development of resistance was evaluated through regular IC50 determinations. **e** Once cultures showed at least a 2-fold shift in IC50 single clones were generated by plating an aliquot of the resistant strain onto compound-containing YPD plates. **f** Two independent clones were picked and the IC50 shift confirmed. IC50 values were calculated by subtracting OD600 nm values at time 0 h from time 18 h. Nonlinear regression on log([inhibitor]) vs. response with variable slope was performed using GraphPad Prism. Cycloheximide was used as a negative control. **g** DNA from clones deemed to be resistant (through a combination of fold shift of IC50 and p-value) was isolated and their whole-genome analyzed. **h** The genomes of the drug-naive parents and the drug-resistant clones were compared and allele differences between these two clones were determined. Data from all in vitro evolutions was analyzed in great detail. To further validate the potential resistance of the identified mutations allelic replacement of these SNVs into the parental line through CRISPR-Cas9 was performed. Graphics created with Biorender.com under BioRender’s Academic License Terms.
adaptive⁴⁰, the presence of one SNV in a resistant clone is not proof that the specific mutation is resistance-conferring. To confirm that some of these mutations directly contribute to the resistance phenotype and rule out the possibility of them being passenger mutations, we used CRISPR/Cas9 technology to introduce 61 altered alleles from the evolved mutants back into the original (unevolved) ABC₁₆-Green Monster strain. Mutations were chosen for validation based on the frequency of mutation and/or whether the gene product was implicated as a potential target for the compound based on literature searches. Successfully reverse-engineered strains were tested in liquid-growth assays using the same compounds from the corresponding IVIEWGA experiments. Using a combination of fold change and p-value in comparing the IC₅₀ values of these edited clones to those of the parental ABC₁₆-Green Monster strain, we verified that 45 genetic changes across 37 unique genes contributed to the observed

---

Fig. 3 Mutations observed in yeast IVIEWGA experiments. a Base transition. Classification of mutation based on base transition type for 1286 SNV mutations obtained via compound selection and absence of compound selection¹⁰⁵. b Classification of the most common mutation types in the dataset and their occurrence in essential vs. nonessential genes. Essentiality data were imported from the Saccharomyces Genome Deletion Project database and proportion of essential vs. nonessential genes that contained missense, synonymous, frameshift, and stop gained mutations were calculated. c Mutation type. Variant classes for 1405 mutations (INDELs and SNVs supplied from Supplementary Data 4) obtained via compound selection versus a mutation dataset from non-compound selection conditions¹⁰⁵. d Circos plot. Circos plot of SNVs (blue), INDELs (orange), and CNVs (cyan) identified through resistance generation, generated with BioCircos R package¹⁰⁶. e-g Intergenic mutations. Plot locating each coding region mutation onto the gene (gray) and intergenic mutation onto the chromosome (orange) based on the calculated distance. Mutations were mapped to their corresponding genomic location using S. cerevisiae S288C genome version R64-2-1. Intergenic mutations are located at no more than 500 bp away from the start/end of the gene.
resistance (Supplementary Data 7). Independent mutations that were repeatedly identified for a specific gene tended to have a high probability of confirming at least a partial resistance phenotype and these gene products were likely to be the direct target of the small molecule. The only exception was RPO21, a subunit of RNA polymerase, which was mutated four separate times with four compounds (two nonsynonymous and two synonymous mutations) but failed to confirm a resistance phenotype after CRISPR/Cas9 editing. However, it is known that mutations in RPO21 result in transcriptional slippage, which may allow cells to better survive cytotoxic drugs that alter nucleotide pools41. For the 15 alleles that did not show a statistically significant IC\textsubscript{50} shift (Supplementary Data 7), we noted that 11 of the resistant clones also carried additional resistance alleles in a highly represented gene such as YRR1 or YRM1 (Supplementary Data 4), two transcription factors involved in multidrug resistance.

Using in vitro evolution for drug target and mechanism of action studies. For compounds with known targets, we frequently identified mutations clustering in the active site of the proposed target molecule. For example, we isolated six clones resistant to flucytosine (Table 1, Supplementary Data 4). Of the nine identified missense or nonsense mutations, six were in the uracil phosphoribosyltransferase domain of FUR1 (probability of enrichment by chance = 1.2 × 10\textsuperscript{−26} using a hypergeometric mean function). Resistance to 5-flucytosine has been reported in multiple clinical isolates of Candida and is typically caused by mutations in genes that encode the enzymes involved in the metabolic transformation of the prodrug. In a study of flucytosine-resistant clinical isolates of C. albicans, mutations in FUR1 were identified42. A homology model (Fig. 4a) revealed that the amino acid changes identified in our in vitro selections are all located near the 5-FUMP binding pocket, suggesting that these changes confer resistance by disrupting 5-FUMP binding.

We obtained four benzoxaborole-resistant clones using the antifungal drug, tavaborole. They were highly resistant and contained six SNVs, four of which (R316T, V400F, V400D, and M493R) were mutations in the 145 amino acid aminoacyl-tRNA synthetase editing domain of CDC60 (p = 1.11 × 10\textsuperscript{−18}, hypergeometric mean function), the gene that encodes leucyl-tRNA-synthetase in yeast. Wild-type yeast can evolve benzoxaborole resistance via amino acid changes both within the ligation editing site of the leucyl-tRNA synthetase and outside the active site70,71, indicating the relevance of the GM model. A LeuRS homology model (Fig. 4b) with a tavaborole ligand docked using QuickVina26 suggests that the observed CDC60 mutations could confer resistance by directly interfering with tavaborole binding to Cdc60.

We also examined compounds used in chemotherapy. Camptothecin is a specific topoisomerase (Top1) inhibitor that binds the DNA/Top1 cleavage complex, preventing DNA religation47. We isolated two camptothecin-resistant yeast clones with three missense mutations, two of which were in TOP1 (G297C and E669*) (Supplementary Data 4). TOP1 mutations can lead to camptothecin resistance in the human HCT116 colon adenocarcinoma cell line when exposed to SN38, a water-soluble camptothcin derivative48,49. A homology model (Fig. 4c)50 was constructed by aligning a partial yeast Top1 crystal structure to a crystal structure of human TOP1 with camptothecin bound (PDB: 1T81)51. This model showed that G297 is located in the core domain of the enzyme near the binding pocket, suggesting that it confers drug resistance by directly impeding compound binding. E669* truncates the entire C-terminal domain, which contains the DNA-binding site52 (Fig. 4c), thus eliminating many protein/DNA contacts and likely impeding the formation of the drug-DNA-protein complex.

Rapamycin, a macrocyclic lactone, and its analog everolimus potentiate inhibit mTOR, a protein kinase component of both the mTORC1 and mTORC2 complexes that controls cell growth and proliferation in many species. Two rapamycin-resistant and three everolimus-resistant clones were isolated in our study. One carried a S1975I mutation in the FKBP12-rapamycin binding domain of mTOR, TOR2, and three carried a mutation in the FKBP-type peptidylprolyl cis-trans isomerase Pfam domain of FPR1, a small peptidylprolyl isomerase that interacts with mTOR (Supplementary Data 4). Recently, a selection with rapamycin in a pdr1 deletion strain of S. cerevisiae BY474153 identified mutations in TOR1, TOR2, and FPR1 that confer resistance to rapamycin.53. One of the reported TOR2 mutations produced a S1975R amino acid change, the same residue we identified as being mutated in our study. A model of the yeast Tor2/Fpr1/rapamycin tertiary complex shows that residue S1975 is near the bound rapamycin molecule (Fig. 4d), suggesting that changes at this location might disrupt the formation of the tertiary complex.

Our collection also contained compounds active against other pathogens. For example, mebendazole, a benzimidazole compound, is among the few effective drugs available for treating soil-transmitted helminths (worms) in both humans and animals. It binds to tubulin, thereby disrupting worm motility.54. We confirmed the antifungal activity55 of mebendazole and obtained two independent resistant clones with nine missense mutations, two of which were in the GTPase domain of the TUB2 gene (R241S and L250F) (Supplementary Data 4), near or at the same residues (R241H and R241C) that confer resistance to the related antimitotic drug, benomyl, which also binds tubulin53,56.

Modeling studies (Fig. 4f) confirm that the binding mode is similar to that of benomyl, which binds with high affinity to the beta subunit of tubulin, thereby disrupting the structure and function of microtubules57. Despite sharing a common target with yeast, helminths and nematodes have benzimidazole-resistance mutations in codons 167, 198, and 200, suggesting conservation of structure and function across phyla.

Alkylphosphocholines such as miltefosine and edelfosine were originally developed as anticancer agents, but recent work has shown that they are also effective against trypanosomatid parasites such as Leishmania and Trypanosoma58–61. The specific target of these drugs remains uncertain. Compound uptake in yeast is known to depend on the membrane transporter Lem62,63, which facilitates phospholipid translocation by interacting with the flipase Dnf164, and Dnf1 is closely related to the gene associated with miltefosine resistance in Leishmania (Ldmt (AY321297), BLASTP e = 2 × 10\textsuperscript{−125}). We identified two independent LEM3 mutations that confer resistance to miltefosine (K134* and Y107*) (Supplementary Data 4). Editing Y107* into the drug-naïve parent restored resistance to both miltefosine and edelfosine (Supplementary Data 7). Both mutations truncate the protein, functionally mimicking a deletion strain. LEM3 is an ortholog of LdROS (ABB05176.1, BLASTP 5 × 10\textsuperscript{−13}), also related to Leishmania miltefosine resistance65.

Revealing the putative target for an uncharacterized antimalarial natural product. Hectochlorin is a natural product from the marine cyanobacterium Lyngbya majuscula66 that has strong antimalarial blood stage activity (IC\textsubscript{50} = 85.60 nM ± 0.96) as well as activity against the ABC16-Green Monster strain (IC\textsubscript{50} = 0.25 µM). We identified six independent disruptive mutations, three of which were in the actin Pfam domain of Act1 (p = 1.9 × 10\textsuperscript{−13}, Supplementary Data 4). We confirmed by CRISPR-Cas9 editing that a
mutation in Act1. The altered amino acids again line a well-defined resistance network glucose transporter of the major facilitator superfamily.

| Gene       | Description                                      | NG | NC | Compounds                                                                 | p-value           |
|------------|--------------------------------------------------|----|----|---------------------------------------------------------------------------|-------------------|
| YRM1       | Zn2-Cys6 zinc-finger transcription factor        | 52 | 13 | See Supplementary Data 4                                                   | 3.53 × 10^{−116} |
| YRR1       | Zn2-Cys6 zinc-finger transcription factor        | 48 | 12 | See Supplementary Data 4                                                   | 2.51 × 10^{−105} |
| PMA1       | Plasma membrane P2-type H + ATPase               | 15 | 5  | GNF-PI-445, Hygromycin B, KA609, Wortmannin,                             | 3.00 × 10^{−24}  |
| BUL1       | Ubiquitin-binding component of the Rsp5p E3 ubiquitin ligase complex | 14 | 11 | See Supplementary Data 4                                                   | 3.92 × 10^{−22}  |
| PDE2       | High-affinity cyclic AMP phosphodiesterase      | 13 | 2  | MMV000570, MMV007181                                                      | 4.76 × 10^{−20}  |
| TPO1       | Polyamine transporter of the major facilitator superfamily | 12 | 5  | GNF-PI-4283, MMV006389, CBR410, CBR572, TCMDC-124263                      | 5.34 × 10^{−18}  |
| ANY1       | Putative protein of unknown function             | 11 | 5  | Amimipryline, MMV019017, Clompiramine, MMV396736, Sertraline             | 5.51 × 10^{−16}  |
| BAP2       | High-affinity leucine permease                   | 10 | 6  | GNF-PI-3703, GNF-PI-3815, GNF-PI-5129, GNF-PI-5468, MMV06389             | 5.19 × 10^{−14}  |
| SIP3       | Putative sterol transfer protein                 | 8  | 3  | GNF-PI-445, Lomerizine, Loratidine                                        | 3.38 × 10^{−10}  |
| INPS3      | Polyphosphatidylinositol phosphatase             | 8  | 1  | MMV000442                                                                 | 3.38 × 10^{−10}  |
| AFT1       | Transcription factor involved in iron utilization| 7  | 3  | MMV085203, MMV1007245, CBR868                                            | 2.28 × 10^{−8}   |
| PDR1       | Transcription factor that regulates the pleiotropic drug response | 7  | 7  | DDD01027481, Ddoxorubicin, MMV000442, MMV007224, MMV667491, CBR668, CBR110 | 2.28 × 10^{−8}   |
| ERG9       | Farnesyl-diphosphate farnesyl transferase       | 7  | 2  | AN7973, MMV1078458                                                        | 2.28 × 10^{−8}   |
| YAP1       | Basic leucine zipper (bZIP) transcription factor | 6  | 4  | Cycloheximide, GNF-PI-4739, DDD01027481, MMV001246                      | 1.34 × 10^{−6}   |
| TOP2       | Topoisomerase II                                 | 6  | 1  | Etopside                                                                  | 1.34 × 10^{−6}   |
| HXT3       | Low-affinity glucose transporter of the major facilitator superfamily | 6  | 3  | Amimipryline, DDD01035522, GNF-PI-445                                    | 1.34 × 10^{−6}   |
| ERG11      | Lanosterol 14-alpha-demethylase                  | 6  | 2  | MMV001239, CBR499                                                         | 1.34 × 10^{−6}   |
| FUR1       | Uracil phosphoribosyltransferase                 | 6  | 1  | Fucityosine                                                               | 1.34 × 10^{−6}   |
| CCR4       | Component of the CCR4-NOT transcriptional complex| 5  | 4  | GNF-PI-2823, GNF-PI-4583, MMV403679, CBR868                               | 6.76 × 10^{−5}   |
| ERG3       | C-5 sterol desaturase                             | 5  | 2  | Miconazole, Posaconazole                                                  | 6.76 × 10^{−5}   |
| FKS1       | Catalytic subunit of 1,3-beta-D-glucan synthase  | 5  | 4  | DDD01027481, CBR113, CBR668, CBR110                                       | 6.76 × 10^{−5}   |
| CDC60      | Cytosolic leucyl-tRNA synthetase                 | 5  | 2  | CBR668, Tavaborole                                                        | 6.76 × 10^{−5}   |
| ROX1       | Heme-dependent repressor of hypoxic genes;       | 5  | 3  | Loratadine, MMV665909, TCMDC-124263                                     | 6.76 × 10^{−5}   |
| PDR3       | Transcriptional activator of the pleiotropic drug resistance network | 5  | 3  | Lapatinib, MMV665794, CBR110                                              | 6.76 × 10^{−5}   |
| OSH3       | Member of an oxysterol-binding protein family    | 5  | 1  | Posaconazole                                                              | 6.76 × 10^{−5}   |
| CS2G       | Endoplasmic reticulum membrane protein           | 4  | 2  | GNF-PI-1618, KAAA726                                                      | 4.76 × 10^{−2}   |
| ELO2       | Fatty acid elongase                              | 4  | 2  | Dooxorubicin, MMV667491                                                  | 4.76 × 10^{−2}   |
| TUP1       | General repressor of transcription                | 4  | 1  | Diethylstilbestrol                                                        | 4.76 × 10^{−2}   |
| RPO21      | RNA polymerase II largest subunit B220           | 4  | 4  | Lapatinib, MMV007181, MMV1469689, CBR110                                  | 4.76 × 10^{−2}   |
| SUR2       | Sphinganine C4-hydroxylase                       | 4  | 1  | MMV667491                                                                | 4.76 × 10^{−2}   |
| VMAT16     | Subunit c of the vacular ATPase                  | 4  | 4  | Lapatinib, MMV019017, MMV396736, MMV665882                                | 4.76 × 10^{−2}   |
| PAN1       | Part of actin cytoskeleton-regulatory complex    | 4  | 2  | Hygromycin B, KA609                                                       | 4.76 × 10^{−2}   |

32 genes identified by compound selection were returned, and the significance threshold for number of mutations occurring in a gene at a rate not expected by chance across the dataset was Bonferroni-corrected (p = 0.035). Altogether we observed 25 highest confidence genes (7x), PDR3 = 0.035). Altogether we observed 140 confidence genes (5x), YAP1 (23x) (Fig. 5b, c). In addition, multiple unique missense mutations were observed in PDR1 (7x), PDR3 (5x) YAP1 (5x), AFT1 (5x), TUP1 (7x), and TUP1 (5x).

Mutations in the transcription factors YRR1 and YRM1 are associated with multidrug resistance in the ABC_M-Green Monster yeast. SNVs in some genes appeared repeatedly across different compound sets. The set of 25 highest confidence genes (mutated five or more times across the dataset) was enriched for DNA-binding transcription factor activity (seven genes, Holm-Bonferroni-corrected p = 0.035). Altogether we observed 140 coding mutations in 24 genes affecting transcription (Fig. 5a). The greatest number of unique allelic exchanges was found in the two transcription factors, YRR1 and YRM1 (23x) (Fig. 5b, c). In addition, multiple unique missense mutations were observed in PDR1 (7x), PDR3 (5x) YAP1 (5x), AFT1 (5x), TUP1 (7x), and TUP1 (7x).
(3x) HAL9 (2x), AZF1 (2x) (Table 1, Supplementary Data 4). With the exception of TUP1, AFT1, and YAPI, all of these transcription factors contain the Zn2C6 fungal-type DNA-binding domain. In fact, we discovered 124 different mutations in 15 different Zn2C6 transcription factors. This Zn2C6 domain family (Pf00172) is only found in fungi: S. cerevisiae has 52 genes with this domain and C. albicans has 225. In this human pathogen, members include FCRI, MRR2, TAC1, PDR1, and PDR3, all genes involved in drug resistance. YRR1 (PDR2), YRM1, PDR1, and PDR3 are all known to be involved in the pleiotropic drug response in S. cerevisiae [70, 71], activating transcription of drug transporters such as PDR5, PDR10, PDR15, YOR1, and SNQ2 (reviewed in ref. 72). Although the GM strain has some of these multidrug efflux pumps deleted, the GM genome retains many other genes that could contribute to multidrug resistance that are under transcriptional control of YRR1 [70]. In addition to statistical enrichment strongly suggesting a driving role in resistance, reverse gene editing by CRISPR/Cas9 of some of the mutations identified in YRR1, AFT1, and TUP1 fully recapitulated the observed resistance phenotype (Supplementary Data 7).

Because the two Zn2C6 transcription factors YRR1 and YRM1 were mutated 100 times for 19 structurally diverse compounds (Fig. 5b–d), we conducted a focused investigation of the mutations and their spatial localization. Remarkably, all resistance-conferring YRR1 and YRM1 mutations were clustered in a ~170 amino acid domain in the C-terminal half of the protein (Fig. 5b, c), which is distal to the DNA-binding domain. We found no mutations in the DNA-binding domain and no mutations in the predicted activation domain at the far C-terminus. Notably, it has been shown that the C-terminal activation domain of Gal4 (activation domain 9aaTAD (857–986)), which interacts with Tra1 protein of the SAGA complex, can be substituted for the activation domain of Yrr1 [70]. Yrr1 binds to the sequence (T/A)CCG(C/T)(G/T)(G/T)(A/T)(A/T), found
upstream of genes involved in multidrug resistance such as *AZR1*, *FLR1*, *SNG1*, *SNQ2*, *APD1*, and *PLB1* 

YRR1 and YRM1 are nonessential genes, and we hypothesized that our evolved resistant strains possessed YRR1 and YRM1 gain-of-function mutations that result in constitutive expression of transcriptional target genes encoding proteins with roles in drug resistance. This hypothesis is motivated in part by the fact that others have reported multidrug resistance-conferring gain-of-function mutations in the related genes *PDR1* and *PDR3* 

To expand on this previous work, we exposed a YRR1 L611F strain (generated using CRISPR/Cas9) to a set of compounds and observed cross-resistance to almost all compounds tested (Supplementary Fig. 2, Supplementary Data 7). Others have found that deleting the YRR1 gene entirely does not significantly increase sensitivity to cytotoxic compounds 

Fig. 5 Mutations in transcription factors are over-represented. a Genes identified with three or more different compounds. Genes (B) with ontology GO:0140110 (transcription regulator activity) are shown in red. YRR1 (b) and YRM1 (c) mutation localization. Distribution of mutations in YRR1 and YRM1 across the amino acid sequence clustered in the C-terminal activation domain. d Scaffolds. Compounds used in selections resulting in YRR1 and YRM1 mutations. e YRR1 single-nucleotide mutations but not loss-of-function mutations constitutively activate transcriptional targets. RT-qPCR was utilized to monitor mRNA levels of YRR1 and YRM1 activated genes. Clones with YRR1 point mutations show increases in mRNA levels of YRR1, SNG1, FLG1, and AZR1 relative to the wild-type strain (GM), but the deletion mutant does not. In the absence of YRR1, associated genes display baseline or lower level of expression. The heatmap indicates fold change normalized to ACT1.
To further test the hypothesis that the YRM1 and YRR1 SNVs are gain-of-function mutations resulting in constitutive expression of additional transporters and other potential resistance genes (including AZR1, FLR1, SNG1, YLR046L, YLL046C, YPL088W, and YLR179C), we used qPCR to directly evaluate the expression of three such target genes (AZR1, FLR1, and SNG1). To this set we added the YRR1 gene itself, since YRR1 activates its own expression via an auto-feedback loop (5e). We examined gene expression in YRR1-mutant strains, in the ABC16-Green Monster strain with a wild-type YRR1 allele, and in the yrr1 deletion clone (Supplementary Data 8). Relative RNA expression levels of the putative target genes AZR1, FLR1, SNG1, and YRR1 are 1.5–140-fold higher in all YRR1 evolved mutant clones tested compared to the parental GM strain; mutant clones also display elevated levels relative to the yrr1 deletion clone (Fig. 5e). This data are further corroborated when using TDH3 or TAF10 as alternative housekeeping genes to ACT1 (Supplementary Data 8).

To assess whether YRR1 mutations confer resistance to specific compounds or elicit a more general resistance response, we evaluated seven different YRR1-mutant clones derived from our resistance selections for resistance to a set of five structurally unrelated compounds. All tested cultures showed strong cross-resistance to all tested compounds (Supplementary Data 7). Taken together, these results strongly support our hypothesis that the identified YRR1 SNVs lead to constitutive transcriptional activation of its target genes involved in the pleiotropic drug response, thereby conferring general resistance to many compounds.

Discussion
To our knowledge, this is one of the most comprehensive and systematic studies of the drug-selected mutational landscape in a model system like yeast. Although genome-wide sets of knockout strains have been used to discover drug targets and to study drug resistance, our approach is different in that we identify SNVs in specific domains that might play a crucial role in compound-target interaction. Since these mutations confer resistance, we hypothesize that many of the SNVs are gain-of-function mutations. This difference in approach allows IVIEWGA to complement other genome-wide knockdown approaches, including those that rely on measures of haploinsufficiency in the presence of compound (HIPHOP). Few genetic tools are needed, and the approach can be applied to any organism that can be subjected to drug pressure and sequencing.

One potential disadvantage of whole-genome evolutionary approaches is that background passenger mutations can accumulate during the prolonged culturing of a fast-dividing organism and some may not contribute to resistance. However, given the enrichment for nonsynonymous mutations in our study, most mutations likely do offer some advantage to the cell even when they are not the primary drivers of resistance. A large dataset like ours can provide clarity and statistical confidence regarding an allele’s importance even in the absence of CRISPR-Cas9 reconfirmation. The examples that are discussed in the manuscript did, in almost all cases, achieve strong statistical significance, with mutations in the same genes or with compounds that are structurally closely related appearing at rates much greater than expected by chance. It should be mentioned that many other mutations were found at rates not expected by chance and were not discussed here for the sake of brevity. For example, we found a strong association between BUL1 and BAP2 mutations and inhibitors of mitochondrial function as well as vacuolar ATPase mutations that were associated with other scaffold families.

The reproducibility of the results for genes and compound families indicates that the approach could be powerful in other fungal species that lack the genetic tools available for S. cerevisiae.

Although others have identified targets of antifungal compounds through deep sequencing of drug-resistant mutants in other fungi, S. cerevisiae is an excellent model for studying antifungal drug resistance in part because it is a haploid. IVIEWGA may be more difficult to apply in diploid species such as Candida albicans since complete loss-of-function mutations may be difficult to evolve and heterozygous gain-of-function mutations may be hard to identify in whole-genome sequencing data.

Another notable finding is the enrichment for Zn2+–C6 transcription factors YRR1 and YRM1 in the set of resistance genes. Though this may be specific to Saccharomyces or even the ABC16-Green Monster strain that was used, smaller-scale studies with specific compounds strongly support our findings (reviewed in ref. 83). Evolution experiments with unmodified S. cerevisiae and fluconazole gave mutations in PDR1. Gallagher et al. mapped the ability of wild-type yeast to resist 4-nitroquinoline 1-oxide to YRR1. In addition, YRR1 was originally identified with selections in unmodified yeast. Zn2+-C6 transcription factors are known to play a major role in the pathogenesis and pleiotropic drug response of pathogenic fungi such as Candida spp., the most commonly clinically relevant fungal pathogens. Examples include TAC1, STB5, and many others (reviewed in ref. 82). Nevertheless, it is plausible that the abundance of YRR1 and YRM1 mutations that we identified only emerges when multiple other drug pumps are deleted, as in the GM strain.

A major unanswered question is how the cell senses increased compound pressure and translates this to increased transcription. A cofactor could bind to the drug-resistance domain in Yrr1 and Yrm1. Alternatively, the observed amino acid changes could increase either the strength of the dimerization of Yrr1 and/or its binding to DNA, causing an increase in the transcription of drug pumps, which would lead to resistance to many compounds irrespective of their MOA. This hypothesis is supported by the fact that (1) the RNA expression levels of the Yrr1 target genes AZR1, FLR1, SNG1, and YRR1 are 2–70-fold higher in all of the tested YRR1-mutant clones when compared to the parental GM strain or the yrr1 deletion lineage and (2) clones with YRR1 mutations confer resistance even to compounds that were not used in selections or that did not yield YRR1 mutations.

The World Health Organization has declared antimicrobial resistance one of the top 10 public health concerns currently facing humanity. While understanding resistance profiles and the rate at which resistance emerges are already key components of drug development pipelines for eukaryotic pathogens like the human malaria parasite Plasmodium falciparum, studies of drug resistance in fungal pathogens remain extremely limited. Adaptive laboratory evolution has proven a useful tool for cataloging resistance variants across multiple microbes, enabling strategic drug design efforts and more. If the goal is to create better drugs for fungal pathogens, more studies like these are urgently needed.

Materials and methods
Yeast strains and clones. All yeast strains and clones used are listed in Supplementary Data 10.

Statistics and reproducibility. To calculate probabilities of enrichment chance for specific allele sets a high accuracy hypergeometric mean function (Excel) was used:

\[
P(X \geq x) = \frac{\binom{k}{x} \binom{N-k}{n-x}}{\binom{N}{n}}
\]

n is the number of different observed alleles in a particular domain or gene for a compound in n selections.

x is the number of independent selections that were performed for a compound.
N is the number of nucleotides in the gene or domain of interest (e.g., 300 bases), or the number of genes in the genome multiplied by the number of n selections.

K is the number of nucleotides in the yeast genome (12.1 Mb), or the number of genes (6000) multiplied by the number of n selections.

A Bonferroni adjustment using the yeast genome size (12.1 x 10^6) or a number of genes (6000) was made to correct for multiple hypothesis testing.

**S. cerevisiae susceptibility and dose-response assays.** To measure compound activity against whole-cell yeast, single colonies of the ABCG1–Green Monster strain were inoculated into 2 mL of YPD media and cultured overnight at 250 RPM in a shaking incubator at 30 °C. Cultures were diluted the following day and 200 μL of log-phase cultures, (OD600 nm readings between 0.1 and 0.2) were added to the wells of a 96-well plate. Eight 1:2 serial dilutions of the compound were subsequently performed, in biological duplicates, with final compound concentrations ranging from 0.1 to 150 μM. After an initial reading of OD600 (time 0 h), the plate was placed in an incubator at 30 °C for 18 h, and OD600 nm determined. IC50 values were calculated by subtracting OD600 nm values at time 0 h from time 18 h. Nonlinear regression on log(inhibitor) vs. response with variable slope was performed using GraphPad Prism. As a negative control, cultures not treated with any compounds were run in parallel.

**GM Growth inhibition evaluation for the MMV Malaria Pathogen Box, and Charles River libraries.** 96-well plates containing 10 ml 10 mM compounds were provided. We first tested these compounds for cytotoxicity of the ABCG1–Green Monster clone in single-dose measurements (150 μM, in biological duplicates). Compound tolerance of GM growth by at least 70% after 18 h (in either replicate) were further characterized using an eight-point dose-response assay (Supplementary Data 1).

**In vitro resistance evolution.** In vitro selections30–38 were performed as outlined in Fig. 2. At least five independent selections were initiated with a single colony of the ABCG1–Green Monster strain. Assorted drug concentrations (corresponding to 1-fold to 3-fold of the final compound concentrations) were added to 50 ml conical tubes containing 50 μl of saturated (OD600 = 1.0–1.5; 1–5 x 10^6/ml cells) ABCG1–Monster cells in 20 ml of YPD medium. The tubes were then cultured at 250 RPM in a shaking incubator at 30 °C. Cultures that achieved OD600 values between OD600 = 1.0–1.5; 14 generations) were diluted 1:400 into fresh media with the inhibitors, and multiple rounds of dilutions (about 2–6 rounds of dilutions) were performed at increasingly higher concentrations. After a culture was able to grow at a compound concentration that was at least equal to 2–3x IC50 compared to the parental IC50, cells from this polyclonal culture were plated onto agar plates containing the inhibitor. Single colonies were isolated, and an eight-point dose-response assay (in biological duplicates) with two-fold dilutions steps and final compound concentrations ranging from 0.1 to 150 μM (depending on the original parental IC50) was performed to determine the IC50 values of the evolved versus parental clones. Genomic DNA from clones that had at least an IC50 shift of 1.5-fold was extracted using the Yeast Genomic DNA kit (cat. No D2002, ZYMO Research).

**Whole-genome sequencing and analysis.** Sequencing libraries using 200 ng genomic DNA were prepared using the Illumina Nextera XT Kit (Cat. No. FC-131-1024, Illumina) following the standard dual indexing protocol, and sequenced on the Illumina HiSeq 2500 in RapidRun mode to generate paired-end reads at least 100 bp in length. Reads from the paired-end FASTQ files were aligned to the S. cerevisiae 288C reference genome (assembly R64-1-1) using BWA-mem and further processed using Picard Tools (http://broadinstitute.github.io/picard/). Quality control alignment and preprocessing workflows were automated using the computational platform Omics Pipe84 to ensure scalable and parallelized analysis. A total of 363 clones were sequenced to an average coverage of 54.6x with an average of 99.7% reads mapping to the reference genome. Additional sequencing quality statistics are given in Supplementary Data 3. SNVs and INDELs were determined using GATK recommendations95, and annotated with a SnpEff96 database built from the GFF supplied on SGD for the desired allelic exchange (Integrated DNA Technologies) containing a 24 bp overlap with the p426 vector backbone. Subsequently, target-specific gRNAs were PCR amplified/transformed into competent E. coli cells and selected on LB-Ampicillin plates. ABCG1–Monster cells expressing Cas9 were simultaneously transformed with 300–500 ng of gene-specific gRNA vector and 1–2 n mole of synthesized donor template (IDT) via a standard lithium acetate method. Transformed cells were plated and selected on methionine and leucine deficient CM-glucose plates. Each engineered mutation was confirmed by Sanger sequencing (Eton Bioscience).

**qPCR.** S. cerevisiae strains were grown in YPD (1% yeast extract, 2% bacto peptone, 2% dextrose) overnight at 30°C. 1 OD600 log-phase cells were harvested and subject to total RNA extraction using Qiagen RNeasy kit, following the manufacturer’s protocol. cDNA was generated using ThermoFisher SuperScript IV First-Strand Synthesis System, following the manufacturer’s protocol using oligo(dT). qPCR was performed with oligonucleotides (Supplementary Table 1) in technical triplicates on a QuantStudio TaqRite SYBR® Green FastMix. Analysis was done using Prism 8. Ct values for each gene of interest were averaged and normalized against ACT1 within each clone (ΔCt). Then each gene of interest was normalized against corresponding genes in the wild-type GM background (ΔΔCt). Fold expression was calculated using the formula: 2−ΔΔCt98. This analysis was done for each of the four biological replicates (Supplementary Data 8).

**Plasmid invasion assay.** The impact of hectochlorin on hepatocellular traversal and invasion by Plasmodium berghei (Pb) sporozoites was measured using a flow cytometry-based assay69. Anopheles stephensi mosquitoes infected with GFP expressing Pb sporozoites (Pb-GFP)97 were purchased from the New York University (NYU) Insectary Core Facility. Approximately 24 h before infection, 1.75 x 10^5 Hah5.51 cells were seeded in 24-well plates using DMEM (Invitrogen cat# 11965-0292) supplemented with 10% FBS (Corning cat# 35-011-CV) and 1% Pen Strep Glutamine (100 Units/ml, Penicillin, 100 µg/ml Streptomycin, and 0.292 mg/ml L-glutamine) (Invitrogen cat# 10378-016) for a final volume of 1 ml. On the day of infection, hectochlorin was added to test wells (final concentration 1 μM) with cytochalasin D (final concentration 1 μM) acting as a positive control for compound inhibition. A non-infected control (DMEM and DMSO final concentration 0.5%) negative control was also utilized to mimic the treated well conditions. Sporozoites were freshly dissected and prepared 2 h prior to infection99. Immediately prior to infection, rhodamine-dextran was added to each test well (final concentration 100 ng/ml) and collected 1 h after infection. The plates were then incubated at 37 °C and 5% CO2 for 2 h. Following this incubation, the cells were washed and the presence of GFP and rhodamine-dextran signals were evaluated using flow cytometry.

**Model building.** We used I-TASSER30 to model proteins without acceptable structures in the Protein Data Bank100. To visually inspect the homology models, we aligned them to the structural templates used for model construction100. We discarded models that had poor I-TASSER C-scores or that we judged to be improbable (e.g., excessively disordered). Where there were no homologous crystal structures with bound ligands for reference, we used docking to predict ligand
binding poses. Specifically, we converted the SMILES strings of the ligands to 3D structures using a beta version of Gypsum-DELPHI and docked the 3D models using QuickVina26 (exhaustiveness = 15). The AutoDock forcefield does not include parameters for boron. To dock tavaborole, we substituted the boron atom with a carbon atom, as recommended on the AutoDock webpage (http://autodock.scripps.edu). We tested both the “C” and “A” atom types as boron substitutes to determine which gave predicted tavaforole poses with the best binding affinities. For heme groups, we manually added a charge of +2 to the iron atom. All protein-structure images were generated using BlendMol104.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
Raw DNA sequences for all 363 yeast clones have been deposited in the Sequence Read Archive (www.ncbi.nlm.nih.gov/sra) under BioProject accession PRJNA592023. All other data are available in the manuscript or the supplementary materials. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

Received: 4 June 2021; Accepted: 21 January 2022;
Published online: 11 February 2022

References
1. Dettman, J. R. et al. Evolutionary insight from whole-genome sequencing of experimentally evolved microbes. Mol. Biol. 21, 2058–2077 (2012).
2. Good, B. H., McDonald, M. J., Barrick, J. E., Lenski, R. E. & Desai, M. M. The dynamics of molecular evolution over 60,000 generations. Nature 551, 45–50 (2017).
3. Barrick, J. E. et al. Genome evolution and adaptation in a long-term experiment with Escherichia coli. Nature 461, 1243–1247 (2009).
4. Lenski, R. E. & Travisano, M. Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. Proc. Natl Acad. Sci. USA 91, 6808–6814 (1994).
5. Dunham, M. J. et al. Characteristic genome rearrangements in experimental evolution of Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 99, 16144–16149 (2002).
6. Araya, C. L., Payen, C., Dunham, M. J. & Fields, S. Whole-genome sequencing of a laboratory-evolved yeast strain. BMC Genomics 11, 88 (2010).
7. Chang, S. L., Lai, H. Y., Tung, S. Y. & Leu, J. Y. Dynamic large-scale chromosomal rearrangements fuel rapid adaptation in yeast populations. PLoS Genet. 9, e1003232 (2013).
8. Albert, T. J. et al. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nat. Methods 2, 951–953 (2005).
9. Toprak, E. et al. Evolutionary pathways to antibiotic resistance under dynamically changing drug selection. Nat. Genet. 44, 101–105 (2011).
10. Cowen, L. E. et al. Evolution of drug resistance in experimental populations of Candida albicans. J. Bacteriol. 182, 1515–1522 (2000).
11. Peter, J. et al. Genome evolution across 1,011 Saccharomyces cerevisiae isolates. Nature 556, 339–344 (2018).
12. Wzinzier, E. A. et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285, 901–906 (1999).
13. Giaever, G. et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418, 387–391 (2002).
14. Hillenmeyer, M. E. et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320, 362–365 (2008).
15. Pudda, F. et al. Genome architecture and stability in the Saccharomyces cerevisiae knockout collection. Nature 573, 416–420 (2019).
16. Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature Methods 58, 511–516 (2019).
17. Yang, Z. & Blommer, M. Genome editing systems across yeast species. Curr. Opin. Biotechnol. 66, 255–266 (2020).
18. Després, P. C., Dubé, A. K., Seki, M., Yachie, N. & Landry, C. R. Perturbing proteomes at single residue resolution using base editing. Nat. Commun. 11, 1871 (2020).
19. Kuroda, K. & Ueda, M. CRISPR Nickase-mediated base editing in yeast. Methods Mol. Biol. 2196, 27–37 (2021).
20. Blair, J. M., Webber, M. A., Baylay, A. J., Ogbofu, D. O. & Piddock, L. J. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42–51 (2015).
48. Miao, Z. H. et al. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res. 67, 8752–8761 (2007).

49. Geminova, C. & Vorobjov, I. Novel mechanistic features associated with resistance to camptothecin. Mol. Cancer 10, 64 (2011).

50. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat. Methods 12, 7–8 (2015).

51. Staker, B. L. et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 48, 2336–2345 (2005).

52. Stewart, L., Redmon, M. R., Qin, X., Hol, W. G. & Champoux, J. J. A model for the mechanism of human topoisomerase I. Science 279, 1534–1541 (1998).

53. Wride, D. A. et al. Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae. Mol. Biol. 420, 3179–3187 (2014).

54. Schulz, J. D., Moser, W., Hurliman, E. & Keiser, J. Preventive chemotherapy in the fight against soil-transmitted helminthiasis: achievements and limitations. Trends Parasitol. 34, 590–602 (2018).

55. Joffe, L. S. et al. The anti-helminthic compound mebendazole has multiple antifungal effects against Cryptococcus neoformans. Front. Microbiol. 8, 535 (2017).

56. Thomas, J. H., Neff, N. F. & Botstein, D. Isolation and characterization of mutations in the beta-tubulin gene of Saccharomyces cerevisiae. Genetics 111, 715–734 (1985).

57. Kohler, P. The biochemical basis of anithelmintic action and resistance. Int. J. Parasitol. 31, 335–341 (2001).

58. Croft, S. L., Snowden, D. & Yardley, V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38, 1041–1047 (1996).

59. Gajate, C. et al. Antitumor alkyl-lysophospholipids induce apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene 31, 2627–2639 (2012).

60. Soto, J. et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33, E57–E61 (2001).

61. Sundar, S. et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352, 1821–1823 (1998).

62. Benes, J. et al. [Shock-wave lithotripsy in the treatment of 12 patients with cholecodocholithiasis using an apparatus manufactured in Czechoslovakia]. Čas. Lék. Česk. 129, 43–46 (1960).

63. Hansen, P. K., Malone, L., Birchmore, J. L. & Nichols, J. W. Lm3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J. Biol. Chem. 278, 36041–36050 (2003).

64. Pomorski, T. et al. Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis. Mol. Biol. Cell 14, 1240–1254 (2003).

65. Srivastava, S. et al. Laboratory conformation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae. Mol. Biol. 420, 3179–3187 (2014).

66. Vorobiev, S. et al. The structure of nonvertebrate actin: implications for the ATP hydrolytic mechanism. Proc. Natl Acad. Sci. USA 100, 5760–5765 (2003).

67. Marquez, B. L. et al. New insights into the pleiotropic drug resistance network for drug discovery. Nature 434, 42–47 (2003).

68. Jungwirth, H. & Kuchler, K. Yeast ABC transporters. Eukaryotic Cell 434, 42–47 (2003).

69. Le Crom, S. et al. New insights into the pleiotropic drug resistance network from genome-wide characterization of the YRR1 transcription factor regulation system. Mol. Cell Biol. 22, 2642–2649 (2002).

70. Kodo, N., Matsuda, T., Doi, S. & Munakata, H. Salicylic acid resistance is conferred by a novel YRR1 mutation in Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun. 434, 42–47 (2013).

71. Jungwirth, H. & Kuchler, K. Yeast ABC transporters—a tale of sex, stress, drugs and aging. FEBS Lett. 580, 1131–1138 (2006).

72. Cui, Z., Hirata, T. & Miyakawa, T. Functional analysis of the promoter of the yeast SNQ2 gene encoding a multidrug resistance transporter that confers resistance to 4-nitroquinoline N-oxide. Biosci. Biotechnol. Biochem. 63, 162–167 (1999).

73. Teixeira, M. C., Dias, P. J., Simões, T. & Sá-Correia, I. Yeast adaptation to resistance to camptothecin. Proc. Natl Acad. Sci. USA 100, 1011–1016 (2003).

74. Madden, T. L., Tatusov, R. L. & Zhang, J. Applications of network BLAST for analyzing next-generation DNA sequencing data. Genomics Informatics 13, 1274–1278 (2015).

75. McMenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for reproducing multiple-omics data analysis. Bioinformatics 31, 1724–1725 (2015).

76. Cingolani, P. et al. A program for annotating and predicting the effects of non-synonymous SNPs, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 2323–2328 (2012).

77. Robinson, J. T. et al. Integrative genomic viewer. Nat. Biotechnol. 29, 24–26 (2011).

78. Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1311–1318 (2008).

79. McNamara, C. W. et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248–253 (2013).

80. Swann, J. et al. High-throughput luciferase-based assay for the discovery of Plasmodium falciparum PI(3)K. Malaria J. 12, 201 (2013).

81. Hulihan, E. et al. Genomic pro- perties of fungal sphingolipids. Front. Microbiol. 5, 583 (2014).

82. Durrant, J. D. BlendMol: advanced macromolecular visualization in Blender. Bioinformatics 31, 2233–2235 (2015).

83. Zhu, Y. O., Siegel, M. L., Hall, D. W. & Petrov, D. A. Precise estimates of mutation rate and spectrum in yeast. Proc. Natl Acad. Sci. USA 111, E2310–E2318 (2014).

84. Cui, Y. et al. BioCircos.js : an interactive Circos JavaScript library for biological data visualization on web applications. Bioinformatics 32, 1740–1742 (2016).
107. März, A. M., Fabian, A. K., Kozany, C., Bracher, A. & Hausch, F. Large FK506-binding proteins shape the pharmacology of rapamycin. Mol. Cell Biol. 33, 1357–1367 (2013).

108. Matuschewski, K., Nunes, A. C., Nussenzweig, V. & Ménard, R. Plasmodium sporozoite invasion into insect and mammalian cells is directed by the same dual binding system. EMBO J. 21, 1597–1606 (2002).

Acknowledgements
DNA sequencing was performed at the University of California, San Diego (UCSD), with support from the Institute of Genomic Medicine Core. We would like to thank MMV for providing us with the Malaria Box, Pathogen Box, and Charles River Libraries. This study was supported in parts by grants from the Bill and Melinda Gates Foundation (OPP10654480, OPP1141300, OPP1171497) to G.M.G. and E.A.W. and by a National Institutes of Health (NIH) award (GM085764) to E.A.W. and T.I. M.R.L. was supported in part by Ruth L. Kirschstein Institutional National Research Award T32 GM008666 from the National Institute of General Medical Sciences. L.E.C. was supported by NIH R01AI20958-01A1. L.E.C. is a Canada Research Chair (Tier 1) in Microbial Genomics & Infectious Disease and co-Director of the CIFAR Fungal Kingdom: Threats & Opportunities program. P.M.K. was supported by grant GM127364 from National Institutes of Health. Bill & Melinda Gates Foundation funding (OPP1107194) supported Calibr at Scripps Research for the discovery of the supplied anti-cryptosporidial compounds. This work was supported by a computer-allocation grant from the University of Pittsburgh’s Center for Research Computing to J.D.D.

Author contributions
E.A.W., S.O., Y.S., P.M.K., L.E.C., D.F.W., A.K.L., J.D.D., R.M.W., and G.M.G. played roles in conceptualization, project administration, and supervision. J.D.D. and E.H. performed modeling and docking studies and assisted with writing. G.M.G., Y.S., S.O., E.V., P.K., A.L.C., J.Sc., G.L., J.Sm., J.Y., M.T., and M.S. performed selections, IC50 determinations, CRISPR/Cas9 allelic exchanges, and target validation. M.R.L., F.G., R.P., R.M.W., and K.P.G. performed sequence analysis and created figures. K.P.G. performed compound library analysis and created figures and tables. A.K.L., D.F.W., P.M.K., M.T., L.E.C., E.L., and L.W. analyzed results. A set of compounds was sourced and provided by W.H.G., M.S.L., and C.W.M. qPCR experiments were performed and analyzed by K.C. Liver cell invasion and FACS assays were done by M.A. T.I. advised on experiments. S.O., E.A.W., and M.R.L. analyzed data, prepared figures and tables, and wrote the manuscript. All authors read and approved the submission.

Competing interests
The authors declare the following competing interests: L.E.C. and L.W. are co-founders and shareholders in Bright Angel Therapeutics, a platform company for development of novel antifungal therapeutics. L.E.C. is a consultant for Boragen, a small-molecule development company focused on leveraging the unique chemical properties of boron chemistry for crop protection and animal health. The remaining authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-022-03076-7.

Correspondence and requests for materials should be addressed to Elizabeth A. Winzeler.

Peer review information Communications Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editor: Luke R. Grinham.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022